Novel approach to Gorlin syndrome: A patient treated with oral capecitabine

Journal of Clinical Oncology

Volumn 29, Issue 14, 2011, Pages

  Beach, Douglas F ^a   Somer, Robert ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; PACLITAXEL;

ADULT; ARTICLE; BASAL CELL NEVUS SYNDROME; CANCER PATIENT; CANCER REGRESSION; CASE REPORT; DISEASE COURSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; BASAL CELL NEVUS SYNDROME; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SKIN NEOPLASMS;

EID: 79955812253     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.3393     Document Type: Article

References (29)

1. Preston DS, Stern RS: Nonmelanoma cancers of the skin. N Engl J Med 327:1649, 1992
2. American Cancer Society: Cancer facts and figures 2000. Atlanta, GA, American Cancer Society, 2001. http://www5.cancer.org/downloads/STT/ F&F00.pdf
3. Hruza LL, Pentland AP: Mechanisms of UV-induced inflammation. J Invest Dermatol 100:35S, 1993
4. Aszterbaum M, Rothman A, Johnson RL, et al: Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol 110:885-888, 1998 (Pubitemid 28237693)
5. Kimonis VE, Goldstein AM, Pastakia B, et al: Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 69:299, 1997
6. Gailani MR, Bale AE: Developmental genes and cancer: Role of patched in basal cell carcinoma of the skin. J Natl Cancer Inst 89:1103, 1997
7. Booth DR: The hedgehog signaling pathway and its role in basal cell carcinoma. Cancer Metastasis Rev 18:261, 1999
8. Dahmane N, Lee J, Robins P, et al: Activation of the transcription factor Gli1 and the Sonic hedgehog signaling pathway in skin tumours. Nature 389:876, 1997
9. Alcedo J, Ayzenzon M, Von Ohlen T, et al: The Drosophila smoothened gene encodes a seven-pass membrane protein, a putative receptor for the hedgehog signal. Cell 86:221, 1996
10. Grachtchouk V, Grachtchouk M, Lowe L, et al: The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO J 22:2741, 2003
11. Farndon PA, Del Mastro RG, Evans DG, et al: Location of gene for Gorlin syndrome. Lancet 339:581, 1992
12. Chenevix-Trench G, Wicking C, Berkman J, et al: Further localization of the gene for nevoid basal cell carcinoma syndrome (NBCCS) in 15 Australasian families: Linkage and loss of heterozygosity. Am J Hum Genet 53:760, 1993
13. Gorlin RJ: Nevoid basal-cell carcinoma syndrome. Medicine 66:98, 1987
14. Lo Muzio L, Nocini PF, Savoia A, et al: Nevoid basal cell carcinoma syndrome. Clinical findings in 37 Italian affected individuals. Clin Genet 55:34, 1999
15. Evans DG, Ladusans EJ, Rimmer S, et al: Complications of the naevoid basal cell carcinoma syndrome: Results of a population based study. J Med Genet 30:460, 1993
16. Cretnik M, Musani V, Oreskovic S, et al: The Patched gene is epigenetically regulated in ovarian dermoids and fibromas, but not in basocellular carcinomas. International Journal of Molecular Medicine 19:875-883, 2007
17. Silverman MK, Kopf AW, Bart RS, et al: Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol 18:471, 1992
18. Wolf DJ, Zitelli JA: Surgical margins for basal cell carcinoma. Arch Dermatol 123:340, 1987
19. Rowe DE, Carroll RJ, Day CL: Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 15:424, 1989
20. Smeets NW, Krekels GA, Ostertag JU, et al: Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: Randomised controlled trial. Lancet 364:1766, 2004
21. Orengo IF, Salasche SJ, Fewkes J, et al: Correlation of histologic subtypes of primary basal cell carcinoma and number of Mohs stages required to achieve a tumor-free plane. J Am Acad Dermatol 37:395, 1997
22. Doctoroff A, Oberlender SA, Purcell SM, et al: Full-face carbon dioxide laser resurfacing in the management of a patient with the nevoid basal cell carcinoma syndrome. Dermatol Surg 29:1236, 2003
23. Foley P: Clinical efficacy of methyl aminolevulinate (Metvix((R))) photodynamic therapy. J Dermatolog Treat 14:15, 2003 (suppl 3)
24. Wilson BD, Mang TS, Stoll H, et al: Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol 128:1597, 1992
25. Goette DK: Topical chemotherapy with 5-fluorouracil. J Am Acad Dermatol 4:633, 1981
26. Shumack S, Robinson J, Kossard S, et al: Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: Comparison of dosing regimens. Arch Dermatol 138:1165, 2002
27. El Sobky RA, Kallab AM, Dainer PM, et al: Successful treatment of an intractable case of hereditary basal cell carcinoma syndrome with paclitaxel. Arch Dermatol 137:827, 2001
28. Dierks C: Small molecules in oncology: GDC-0449: Targeting the Hedgehog signaling pathway. Recent Results in Cancer Res 184:235-238, 2010
29. Schellens JHM: Capecitabine. Oncologist 12:152-155, 2007